Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-LRG1 knockdown
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intravenous
01
Overview
AAV-LRG1 knockdown is an experimental gene therapy designed to reduce the expression of Leucine-rich alpha-2-glycoprotein 1 (LRG1) in vascular endothelial cells. LRG1 is a secreted glycoprotein known to promote pathological angiogenesis and vascular instability. In the context of cancer-accelerated atherosclerosis, LRG1 is upregulated via a TNF-driven pathway, leading to increased intraplaque neovascularization and hemorrhage. By using an adeno-associated virus (AAV) vector to deliver a knockdown construct (such as shRNA) specifically to the endothelium, this therapy aims to stabilize atherosclerotic plaques and mitigate the cardiovascular risks associated with systemic inflammation in cancer patients.
- Other names
- vascular-targeted AAV-mediated LRG1 knockdownendothelial-targeted LRG1 knockdown
02
Targets
LRG1 (Leucine-rich alpha-2-glycoprotein 1)
Beyond the preview
Go deeper on AAV-LRG1 knockdown.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-LRG1 knockdown.